Gene Therapy Side Effects

Get health & wellness advice into your inbox

Your privacy is important to us. Any information you provide to us via this website may be placed by us on servers. If you do not agree to these placements, please do not provide the information.

Best Milk Alternative

Introduction

Have you ever wondered about cures for hereditary diseases? Getting down to the root cause of the problem? For many years, around 7,000 rare diseases have affected 10% of the American population, which is only one example!1 Many researchers have dedicated their lives to pursuing the development of gene therapies for the purpose of reducing this statistic. So, what is the role of gene therapy in this?

Historically, gene therapy has been a concept since 1972, illustrated clearly by Theodore Friedmann and Richard Roblin.2 This method of therapy involves the modification of a person’s genes to treat or cure diseases. This can be done through:2

  • Replacing a disease-causing gene with a healthy copy of that gene
  • Turning off a disease-causing gene that was malfunctioning
  • Introducing a new or modified gene into the body to help treat a particular illness or disease

However - like any other therapy - side effects are a concern, and this is especially important because tampering with the wrong genes can have detrimental effects on our health and well-being.

Overview of gene therapy

Types of gene therapy

There are different types of gene therapies, which are summarised below:3

  1. Somatic gene therapy: this form of therapy involves changing and modifying a patient’s genes without affecting their germ cells (sperm and egg cells). Hence, changing the patient’s genes will not affect their children and future generations
  2. Germline gene therapy: this form of therapy is like somatic gene therapy. However, it deals with changes and modifications in the germ cells or early stages of embryonic development. Hence, these genetic changes will be passed on to the patient’s children and future generations

Mechanisms of gene therapy

To understand gene therapy, we must first address the basics which are the genes. So, what are genes? Genes are the unit of inheritance; they are passed from the previous generation (parents) to the offspring and contain the information required for the physical and biological properties of the offspring.4

These genes have various biological codes that produce specific proteins that will contribute to different functions within the body.4 However, these genes can also be carriers of disease where certain mutations or abnormal changes to the biological codes can lead to the formation of illness.3

This brings to light the importance of gene therapy and its aim to treat such scenarios, however it is important to keep in mind that gene editing can have unpredictable effects on future generations if the gene therapy is targeted to germline (sperm and egg) cells.3

Gene therapy has several targets, including both cells and tissues:1,5,6,7,8

  1. Muscle cells: muscular dystrophies and other muscle-related disorders can be targeted by delivering therapeutic genes to muscle cells
  2. Blood cells: hematopoietic stem cells (blood producing cells) that stay in the bone marrow can be a target for disorders (i.e. certain types of anaemia or immunodeficiency diseases)
  3. Retinal cells: the target is cells in the retina, and to treat certain types of inherited blindness or retinal degenerative disorders
  4. Central nervous system (CNS): gene therapy is being studied for the treatment of neurodegenerative disorders, such as Parkinson's disease
  5. Immune cells (T cells): gene modification of T cells in cancer patients can be performed to enhance their ability to target and destroy cancer cells
  6. Bone marrow cells: targeting hematopoietic stem cells in the bone marrow to treat blood disorders, including genetic disorders like thalassemia or sickle cell anaemia
  7. Endothelial cells: in cardiovascular gene therapy, endothelial cells lining blood vessels may be targeted to address conditions like atherosclerosis or to promote blood vessel growth (angiogenesis) in ischemic tissues
  8. Lung cells: targeting cells within the respiratory system to address conditions like cystic fibrosis

Common side effects

Side effects of gene therapy can be divided into immediate/short-term and long-term side effects.

Immediate and short-term Side effects

Immediate and short-term side effects of gene therapy include9,10,11:

  • Inflammation at the site of injection
  • Fever and flu-like symptoms
  • Allergic reactions to components of the gene therapy
  • Temporary increase in liver enzymes
  • Pain and fatigue

Long-term side effects:

When assessing the long-term effects of gene therapy, multiple factors must be considered such as the specific gene therapy approach, the targeted cells and the patient. However, long-term effects are harder to study and require more data and clinical studies. Regardless, some of the long-term side effects include12:  

  • Off-target effects: there is a potential for gene therapy to affect other genes and cellular functions that are not the target. Hence, posing a risk to the health of the patient
  • Immune response: since gene therapy includes the use of vectors and genetic material, an immune response might be triggered in some individuals over time. This can compromise the efficacy of this form of treatment
  • Genome instability and integration: studying the stability of the genome post-therapy and the possibility of insertional mutagenesis is a concern in this therapy

Patient-specific considerations

Before commencing gene therapy, the patient’s attributes are important to consider. This includes their age, health status and genetic predisposition:13,14

  • The effects of treatment correlates with the age of the patient
  • Pre-existing conditions, previous treatments and any potential contraindications have to be considered to minimise the risk to patients
  • Genetics certainly plays a big role in the treatment response; variable gene expression patterns, ethnic diversity and individualised immune response are all factors that affect the success of gene therapy

Case studies

There have been several successful cases of gene therapy demonstrating its potential in treating various genetic disorders. Some of them include15,16,17:

  1. Severe Combined Immunodeficiency (SCID-X1): One of the earliest successful cases of gene therapy involved treating children with X-linked SCID-X1, which is commonly known as "bubble boy" disease. Researchers successfully used gene therapy to correct the genetic mutation causing SCID-X1, restoring the immune function in some patients
  2. Haemophilia B: this is a bleeding disorder caused by a deficiency of clotting factor IX. Gene therapy trials have seen success in this area where some patients have experienced significant and sustained increases in clotting factor levels, which reduced the frequency and severity of bleeding episodes
  3. Leber Congenital Amaurosis (LCA): is a rare genetic retinal degenerative disorder that leads to severe vision impairment. Successful gene therapy cases were reported, where the addition of a functional copy of the RPE65 gene into the retina resulted in improved vision in some patients

Mitigation and management of side effects

Before therapy is commenced, it is important to perform pre-treatment screening to assess the compatibility of the patient with the chosen therapy. During treatment, the patient should be monitored for any issues and should continue to be monitored after the treatment has been performed to address any side effects that could take place.

However, in cases of side effects occurring, supportive care and anti-inflammatory medications are usually used to treat short-term side effects. In cases of gene therapy affecting the blood cells, blood product support (i.e. transfusions) can be administered to help mitigate the effects.18

Ethical considerations

When considering a treatment like gene therapy, ethics becomes an issue and a big topic to debate over especially when involving germline therapies. It is important to make sure that the patient is made aware of the details of the procedure as informed consent is crucial. Additionally, this method involves the collection and manipulation of genetic information; hence, it is important to protect the privacy of the individuals. Furthermore, different countries and even cities within the same country can have different values, cultures, and religions, all of which can affect the ethical outlook on gene therapy and its implications.

Therefore, addressing these ethical considerations requires ongoing dialogue and collaboration among scientists, healthcare professionals, policymakers, ethicists and the public. Ethical guidelines, regulatory frameworks and public engagement efforts aim to navigate the complex landscape of gene therapy responsibly and ethically.

Future directions

When thinking about the future of gene therapy, there are several points to keep in mind:19,20

  • Global collaboration and standardisation: where increased collaboration between researchers, clinicians and regulatory bodies can help standardise protocols, ethical guidelines and implement the best practice
  • Advancements in vector technology: improvements in viral and non-viral vector technologies (such as nanoparticles) are essential for the enhanced safety and efficiency of gene delivery. Novel vectors with better targeting capabilities, reduced immunogenicity, and improved cargo capacity are being developed
  • Gene editing techniques: the development and refinement of gene editing techniques, such as CRISPR-Cas9, are expected to open new possibilities for precise genetic modifications. This may enable the correction of specific mutations associated with various diseases

Summary

In the modern age, technological advancement has seen a rapid improvement, reaching out to molecular and genetic levels. Gene therapy poses as a promising and important tool for therapeutics. However, its side effects are a big concern for the health of potential receivers of gene therapy, including unpredictable immune responses and off-target effects. Hence, it is important that efforts are made to focus on more extensive research in this area to unlock its full potential whilst reducing side effects.

References

  1. Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, et al. Current clinical applications of in vivo gene therapy with aavs. Mol Ther [Internet]. 2021 Feb 3 [cited 2024 Feb 16];29(2):464–88. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854298/
  2. Ma CC, Wang ZL, Xu T, He ZY, Wei YQ. The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnology Advances [Internet]. 2020 May 1 [cited 2024 Feb 16];40:107502. Available from: https://www.sciencedirect.com/science/article/pii/S0734975019302022 
  3. Evans JH. Setting ethical limits on human gene editing after the fall of the somatic/germline barrier. Proc Natl Acad Sci USA [Internet]. 2021 Jun [cited 2024 Feb 16];118(22):e2004837117. Available from: https://pnas.org/doi/full/10.1073/pnas.2004837117
  4. Gene [Internet]. [cited 2024 Feb 16]. Available from: https://www.genome.gov/genetics-glossary/Gene
  5. Leidner R, Sanjuan Silva N, Huang H, Sprott D, Zheng C, Shih YP, et al. Neoantigen t-cell receptor gene therapy in pancreatic cancer. N Engl J Med [Internet]. 2022 Jun 2 [cited 2024 Feb 16];386(22):2112–9. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2119662 
  6. Badawy SM, Beg U, Liem RI, Chaudhury S, Thompson AA. A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy. Blood Adv [Internet]. 2021 Jan 26 [cited 2024 Feb 16];5(2):570–83. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839355/
  7. Valanti EK, Dalakoura-Karagkouni K, Siasos G, Kardassis D, Eliopoulos AG, Sanoudou D. Advances in biological therapies for dyslipidemias and atherosclerosis. Metabolism [Internet]. 2021 Mar 1 [cited 2024 Feb 16];116:154461. Available from: https://www.sciencedirect.com/science/article/pii/S0026049520303255
  8. Maule G, Arosio D, Cereseto A. Gene therapy for cystic fibrosis: progress and challenges of genome editing. International Journal of Molecular Sciences [Internet]. 2020 Jan [cited 2024 Feb 16];21(11):3903. Available from: https://www.mdpi.com/1422-0067/21/11/3903
  9. Silver E, Argiro A, Hong K, Adler E. Gene therapy vector-related myocarditis. International Journal of Cardiology [Internet]. 2024 Mar 1 [cited 2024 Feb 16];398:131617. Available from: https://www.sciencedirect.com/science/article/pii/S0167527323017072
  10. Brenner AJ, Peters KB, Vredenburgh J, Bokstein F, Blumenthal DT, Yust-Katz S, et al. Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study. Neuro Oncol [Internet]. 2020 May [cited 2024 Feb 16];22(5):694–704. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229257/
  11. Botto C, Rucli M, Tekinsoy MD, Pulman J, Sahel JA, Dalkara D. Early and late stage gene therapy interventions for inherited retinal degenerations. Progress in Retinal and Eye Research [Internet]. 2022 Jan 1 [cited 2024 Feb 16];86:100975. Available from: https://www.sciencedirect.com/science/article/pii/S1350946221000367
  12. Han HA, Pang JKS, Soh BS. Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing. J Mol Med [Internet]. 2020 May 1 [cited 2024 Feb 16];98(5):615–32. Available from: https://doi.org/10.1007/s00109-020-01893-z
  13. Delmaghani S, El-Amraoui A. Inner ear gene therapies take off: current promises and future challenges. Journal of Clinical Medicine [Internet]. 2020 Jul [cited 2024 Feb 16];9(7):2309. Available from: https://www.mdpi.com/2077-0383/9/7/2309 
  14.  Dowaidar M. GENOME-WIDE ASSOCIATION STUDIES (GWAS) HAVE REVOLUTIONIZED OUR VIEW OF HUMAN HEALTH AND DISEASE GENETICS AND OFFERED NOVEL GENE THERAPY TARGETS. Journal of Clinical Otorhinolaryngology, Head, and Neck Surgery [Internet]. 2023 [cited 2024 Feb 16];27(1). Available from: https://www.lcebyhkzz.cn/article/view/2023/4024.pdf 
  15. Sayed N, Allawadhi P, Khurana A, Singh V, Navik U, Pasumarthi SK, et al. Gene therapy: Comprehensive overview and therapeutic applications. Life Sciences [Internet]. 2022 Apr 1 [cited 2024 Feb 16];294:120375. Available from: https://www.sciencedirect.com/science/article/pii/S0024320522000753
  16. Blanco E, Izotova N, Booth C, Thrasher AJ. Immune reconstitution after gene therapy approaches in patients with x-linked severe combined immunodeficiency disease. Frontiers in Immunology [Internet]. 2020 [cited 2024 Feb 16];11. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.608653
  17.  Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, et al. Gene therapy with etranacogene dezaparvovec for hemophilia b. N Engl J Med [Internet]. 2023 Feb 23 [cited 2024 Feb 16];388(8):706–18. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2211644
  18.  Shander A, Goobie SM, Warner MA, Aapro M, Bisbe E, Perez-Calatayud AA, et al. Essential role of patient blood management in a pandemic: a call for action. Anesth Analg [Internet]. 2020 Apr 20 [cited 2024 Feb 16];10.1213/ANE.0000000000004844. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173035/
  19. Uddin F, Rudin CM, Sen T. Crispr gene therapy: applications, limitations, and implications for the future. Frontiers in Oncology [Internet]. 2020 [cited 2024 Feb 16];10. Available from: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.01387
  20. Zu H, Gao D. Non-viral vectors in gene therapy: recent development, challenges, and prospects. AAPS J [Internet]. 2021 Jun 2 [cited 2024 Feb 16];23(4):78. Available from: https://doi.org/10.1208/s12248-021-00608-7

Get health & wellness advice into your inbox

Your privacy is important to us. Any information you provide to us via this website may be placed by us on servers. If you do not agree to these placements, please do not provide the information.

Best Milk Alternative
[optin-monster-inline slug="yw0fgpzdy6fjeb0bbekx"]
This content is purely informational and isn’t medical guidance. It shouldn’t replace professional medical counsel. Always consult your physician regarding treatment risks and benefits. See our editorial standards for more details.

Get our health newsletter

Get daily health and wellness advice from our medical team.
Your privacy is important to us. Any information you provide to this website may be placed by us on our servers. If you do not agree do not provide the information.

Tatiana Abdul Khalek

PhD, Anglia Ruskin University, UK

I am a PhD student in Biomedical Science at Anglia Ruskin university and work as a quality control (QC) analyst (microbiology/chemistry) at EuroAPI. I have a MSc in Forensic Science from Anglia Ruskin (Cambridge) and I had experience in different roles such as quality lab technician at Fluidic Analytics, Research Assistant/Lab Manager at Cambridge University and Forensic Analyst at the The Research Centre in Topical Drug Delivery and Toxicology, University of Hertfordshire.

My PhD revolves around the use of nanoparticles and their role in cartilage degradation, as well as their potential as drug delivery vehicles for the treatment of diseases such as leukaemia.

Leave a Reply

Your email address will not be published. Required fields are marked *

my.klarity.health presents all health information in line with our terms and conditions. It is essential to understand that the medical information available on our platform is not intended to substitute the relationship between a patient and their physician or doctor, as well as any medical guidance they offer. Always consult with a healthcare professional before making any decisions based on the information found on our website.
Klarity is a citizen-centric health data management platform that enables citizens to securely access, control and share their own health data. Klarity Health Library aims to provide clear and evidence-based health and wellness related informative articles. 
Email:
Klarity / Managed Self Ltd
Alum House
5 Alum Chine Road
Westbourne Bournemouth BH4 8DT
VAT Number: 362 5758 74
Company Number: 10696687

Phone Number:

 +44 20 3239 9818
arrow-right